Acute Coronary Syndrome
Conditions
Keywords
enoxaparin, tirofiban, percutaneous intervention, platelet inhibition, CD40L, Mac-1, prothrombin fragment 1+2.
Brief summary
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop blood platelets working and so improve the success of the procedure. Individual patients may vary in the dose of the drug required. New platelet tests have been developed which can be performed near the patient and possibly immediately tell the doctor the degree of platelet inhibition achieved so that the dose can be adjusted accordingly. This study aims to investigate if these platelet tests indicate if new anticoagulants are more effective at inhibiting platelet function than the traditional anticoagulants. The study will demonstrate if these newer drugs improve blood flow through the heart muscle and thereby provide better long term outcomes for patients undergoing percutaneous intervention.
Detailed description
Objectives: The study assessed the benefit of high bolus dose tirofiban with enoxaparin compared to unfractionated heparin. Introduction: The benefit of the use of glycoprotein IIb/IIa inhibitors with low molecular weight heparins in high risk patients undergoing percutaneous intervention (PCI) over traditional unfractionated heparin (UFH) is debated. Methods; The study is a prospective single center open-label trial of patients with high-risk acute coronary syndrome treated with PCI who were randomised to anticoagulation with UFH or enoxaparin with 'high dose' (25 mcg/kg bolus) tirofiban This study measured a panel of platelet activation markers, inflammatory biomarkers and thrombus generation between the two groups.
Interventions
DRUGEnoxaparin
Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
DRUGTirofiban
DRUGunfractionated heparin
Sponsors
Sanofi
Merck Sharp & Dohme LLC
The Prince Charles Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients were recruited from those undergoing PCI with a planned placement of an intracoronary stent * Including patients with unstable angina pectoris, acute coronary syndrome or NSTEMI * Experienced ischaemic pain at rest * Lasting 10 minutes and occurring within 7 days before enrollment * As well as one of the following: ECG changes: New or presumably new ST-segment depression greater than or equal to 0.1 mV (1 mm), or transient (\< 30 minutes) ST-segment elevation greater than or equal to 0.1 mV (1 mm) in at least 2 contiguous leads * Abnormal cardiac enzymes within the 24 hours before enrollment, defined as elevated Troponin I defined as elevated Troponin I (above the normal reference -High-risk angiographic features that included intraluminal filling defect, angiographically visible thrombus eccentric lesion, type, location in a proximal major vessel and thrombolysis in myocardial infarction (TIMI) flow of II or less
Exclusion criteria
* Increased bleeding risk: ischaemic stroke within the last year or any previous haemorrhagic stroke, tumour or intracranial aneurysm; * Recent (\<1 month) trauma or major surgery (including bypass surgery); * Active bleeding * Unexplained clinically significant bleeding, thrombocytopenia (platelet count \< 100 x 109/L) or history of thrombocytopenia with GP IIb/IIIa, heparin or enoxaparin therapy * Angina from secondary causes such as severe uncontrolled hypertension (systolic blood pressure \> 180 mm Hg despite treatment) * Valvular disease, congenital heart disease, hypertrophic cardiomyopathy, -Thrombolytic therapy within preceding 24 hours * Receiving antiIIb/IIIa therapy * Creatinine clearance of \<30 mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombus generation as determined by Prothrombin fragment 1+2, D-dimer | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| A panel of platelet activation markers:P selectin, MAC-1, PMAs, factor V/Va,Platelet inhibition as assessed by whole blood aggregometry | 10 minutes , 24 hours |
| Inflammatory biomarkers :CD40L,vWF and CRP | 10 minutes,24 hours |
Countries
Australia
Outcome results
None listed